Functional analysis of the most significant stock exchange characteristics-a case study of the Swiss stock exchange

The aim of this paper is to review transactions on the Swiss Stock Exchange and changes in key performance measurement indicators in the period of 2018-2019. Special attention is paid to the characteristics and functioning of the Swiss Stock Exchange and proving whether and to what extent the Swiss Stock Exchange functions in a different way from other world stock exchanges. The results indicate that it is necessary to have stable market movements in order to be able to have an adequately developed stock exchange (which is already known in the case of the Swiss financial system). Furthermore, most of the financial assets on the Swiss Stock Exchange are traded electronically and finally, current speculations about the existence of innovative approaches for the development of a cryptocurrency that will potentially be pegged to the franc (a certain "stable coin") were investigated.

Blockchain adoption will grow amid bitcoin volatility

Subject Crypto market dynamics. Significance The market capitalisation of cryptocurrencies fell to below 250 billion dollars on April 6 from a record high of 827 billion on January 7. Greater regulation, coupled with more volatile global equity markets and the April 15 US tax filing deadline had prompted substantial cryptocurrency selling. However, the valuation has since recovered to more than 325 billion dollars, supported by the US deadline passing, a seminal paper on April 10 by Blossom Finance declaring bitcoin investment allowable under Sharia law and, most importantly, interest in uses for blockchain continuing to grow. Impacts Many crypto hedge funds have shut, many ICOs have failed and this will continue, but among the blockchain firms there will be big successes. The Swiss stock exchange plans to launch a cryptocurrency version of the Swiss franc; Switzerland will expand as an ICO hub. The rise in financial market volatility since February will intensify and persist as global trade tensions are increasing.

Financial accounts reports

Basilea Pharmaceutica AG is a Swiss-based biotechnology company whose shares are traded on the Swiss Stock Exchange. It is developing antibacterial and antifungal drugs along with dermatology treatments. The company was founded in October 2000 as a wholly owned subsidiary of F. Hoffmann-La Roche, which subsequently sold over half of the company's shares to other investors but retained approximately 33 per cent of the company at 31st December, 2004. The company's pipeline consists of the following compounds: